Role of Interleukin-2 Activated MHC-Nonrestricted Lymphocytes in Antileukemia Activity and Therapy

References

• Lotzová E., Herberman R. B. Interleukin-2 and Killer Cells in Cancer. CRC Press, Inc., Boca Raton, FL 1990, (Assoc. Ed.)
   Google Scholar
• Lotzová E., Savary C. A., Herberman R. B. Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J. Immunol 1987; 138: 2718–2727
   PubMed Web of Science ®Google Scholar
• Lotzová E., Savary C. A., Herberman R. B. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leukemia Res. 1987; 11: 1059–1066
   PubMed Web of Science ®Google Scholar
• Lotzová E., Savary C. A., Totpal K., Schachner J., Lichtiger B., McCredie K. B., Freireich E. J. Highly oncolytic adherent lymphocytes: Therapeutic relevance for leukemia. Leukemia Res. 1991; 15: 245–254
   PubMed Web of Science ®Google Scholar
• Lotzová E. Role of natural killer cells in defense against leukemia. Therapeutic considerations. Nat. Immun. Cell Growth Regul 1988; 7: 170–179
   PubMedGoogle Scholar
• Adler A., Chervenick P. A., Whiteside T. L., Lotzová E., Herberman R. B. Interleukin-2 induction of lympho-kine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 1988; 71: 709–716
   PubMed Web of Science ®Google Scholar
• Crossland K. D., Lee V. K., Chen W., Riddell S. R., Greenberg P. D., Cheever M. A. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemi in vivo. J. Immunol. 1991; 146: 4414–4420
   PubMed Web of Science ®Google Scholar
• Oshimi K., Oshimi Y., Akutsu M., Takei Y., Saito H., Okada M., Mizoguchi H. Cytotoxicity of interleukin-2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 68: 938–948
   PubMed Web of Science ®Google Scholar
• Meuer S. C., Hussey R. E., Hodgdon J. C., Hercend T., Schlossman S. F., Reinherz E. G. Surface structures involved in target recognition by human cytotoxic T lymphocytes. Science 1982; 218: 471–473
   PubMed Web of Science ®Google Scholar
• Lotzová E., Herberman R. B. Immunobiology of Natural Killer Cells. CRC Press, Inc., Boca Raton 1986; Vols I and II, (assoc. ed.)
   Google Scholar
• Lotzová E., Ades E. W. Natural killer cells: Definition, heterogeneity, lytic mechanism, functions, and clinical application. Nat. Immun. Cell Growth Regul 1989; 7: 249–252
   Google Scholar
• Savary C. A., Lotzová E. Phylogeny and ontogeny of NK cells. Immunobiology of Natural Killer Cells, E. Lotzová, R. B. Herberman. CRC Press, Inc., Boca Raton 1986; 45–61, assoc. ed.
   Google Scholar
• Lotzová E., Herberman R. B. Reassessment of LAK phenomenology-a review. Nat. Immun. Cell Growth Regul 1987; 6: 109–115
   PubMedGoogle Scholar
• Lotzová E., Savary C. A., Freedman R. S., Edwards C. L., Wharton J. T. Recombinant IL-2 activated NK cells mediate LAK activity against ovarian cancer. Int. J. Cancer 1988; 42: 225–231
   PubMed Web of Science ®Google Scholar
• Herberman R. B., Balch C., Bolhuis R., Golub S., Hiserodt J., Lanier L. L., Lotzová E., Phillips J. H., Riccardi C., Ritz J., Santoni A., Schmidt R. E., Uchida A., Vujanovic N. Most lymphokine activated killer (LAK) activity mediated by blood and splenic lymphocytes is attributable to stimulation of natural killer (NK) cells by interleukin-2. Immunology Today 1987; 8: 178–181
   PubMedGoogle Scholar
• Lotzová E., Herberman R. B. Interleukin-2 and Killer Cells in Cancer. CRC Press, Inc., Boca Raton 1990, (assoc. ed.)
   Google Scholar
• Lanier L. L., Phillips J. H. A schema for the classification of cytotoxic lymphocytes based on T cell antigen receptor gene rearrangement and Fc receptor (CD 16) or NKH-1/Leu-19 antigen expression. Natural Immunity, Cancer and Biological Response Modification, E. Lotzová, R. B. Herberman. Karger, Basel 1986; 10–18
   Google Scholar
• Lotzová E., Savary C. A. Function of interleukin-2 activated NK cells in leukemia resistance and treatment. Interleukin-2 and Killer Cells in Cancer, E. Lotzová, R. B. Herberman. CRC Press, Inc., Boca Raton, FL 1990; 41–56, assoc. ed.
   Google Scholar
• Lotzová E. Role of natural killer cells in defense against leukemia: Therapeutic considerations. Afar. Immun. Cell Growth Regul. 1988; 7: 170–179
   PubMedGoogle Scholar
• Ortaldo J., Kantor R., Segal D., Bolhuis R., Bino T. Identification of a proposed NK receptor. Natural Killer Cells and Host Defense, International Natural Killer Cell Workshop, Hilton Head, SC, 1988, E. Ades, C. Lopez. Karger, BaselSwitzerland 1989; 221–226
   Google Scholar
• Anderson S. K. Molecular cloning of human and murine natural killer cell tumor recognition proteins. NK Cell Mediated Cytotoxicity: Receptors, Signalling, and Mechanisms, R. B. Herberman. CRC Press, Inc, Boca Raton, FL, (in press)E. Lotzová and assoc. ed.
   Google Scholar
• Evans D. L., Jaso-Friedmann L., Smith E. E., Jr, John A., St., Koren H. S., Harris D. T. Identification of a putative antigen receptor on fish nonspecific cytotoxic cells with monoclonal antibodies. J. Immunol. 1988; 141: 324–332
   PubMed Web of Science ®Google Scholar
• Harris D. T., Jaso-Friedmann L., Evans D. L. Modulation of function-associated molecules on natural killer cells alters recognition and cytotoxicity. NK Cell Mediated Cytotoxicity: Receptors, Signalling, and Mechanisms, R. B. Herberman. CRC Press, Inc, Boca Raton, FL, (in press)ed., E. Lotzová and assoc.
   Google Scholar
• Giorda R., Rudert W. A., Vavassori C., Chambers W. H., Hiserodt J. C., Trucco M. NKR-P1, a signal transduction molecule on natural killer cells. Science 1990; 249: 1298–1300
   PubMed Web of Science ®Google Scholar
• Perussia B., Acuto O., Terhorst C., Faust J., Lazarus R., Fanning V., Trinchieri G. Human natural killer cells analyzed by B73.1 a monoclonal antibody blocking Fc receptor functions. II. Studies of B73.1 antibody-antigen interaction on the lymphocyte membrane. J. Immunol 1983; 130: 2142–2148
   PubMed Web of Science ®Google Scholar
• Inverardi L., Witson J. C., Faud S. A., Winkler-Pickett R. T., Ortaldo J. R., Bach F. H. CD3 negative “small agranular lymphocytes” are natural killer cells. J. Immunol 1991; 146: 4048–1052
   PubMed Web of Science ®Google Scholar
• Caligiuri M. A., Zmuidzinas A., Manley T. J., Levine H., Smith K. A., Ritz J. Functional consequences of interleukin-2 receptor expression on resting human lymphocytes. J. Exp. Med. 1990; 171: 1509–1526
   PubMed Web of Science ®Google Scholar
• Robertson M. J., Ritz J. Role of IL-2 receptors in NK cell activation and proliferation. Cell Mediated Cytotoxicity: Receptors, Signalling, and Mechanisms, R. B. Herberman. CRC Press, Inc., Boca Raton, (in press) ed., E. Lotzová and assoc
   Google Scholar
• Herberman R. B. Overview and perspective: Natural resistance mechanisms. Macrophages and Natural Killer Cells: Regulation and Function, N. Sorkin. Plenum Press, New York 1982; 799–808
   Google Scholar
• Leung K. H., Fischer D. G., Koren H. S. Erythromyeloid tumor cells (K-562) induce PGR synthesis in human peripheral blood monocytes. J. Immunol. 1983; 131: 445–449
   PubMed Web of Science ®Google Scholar
• Melder R. J., Whiteside T. L., Vujanovic N. L., Hiserodt J. C., Herberman R. B. Human adherent lymphokine-activated killer (A-LAK) cells: a new approach to generating antitumor effectors for adoptive immunotherapy. Cancer Res. 1988; 48: 3461–3469
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Grimm E., Mazumder A., Strausser J. L., Rosenberg S. A. In vitro growth of cytotoxic human lymphocytes: IV. Lysis of fresh and autologous tumor by lymphocytes cultured in T cell growth factor (TCGF). Cancer Res. 1981; 41: 4420–4425
   PubMed Web of Science ®Google Scholar
• Lotzová E., Savary C. A. Generation of NK cell activity from human bone marrow. J. Immunol 1987; 139: 279–284
   PubMed Web of Science ®Google Scholar
• Lotzová E., Savary C. A., Pollock R. E., Fuchshuber P. Immunologic and clinical aspects of natural killer cells in human leukemia. Nat. Immun. Cell Growth Regul 1990; 9: 173–181
   PubMedGoogle Scholar
• Ramsdell F., Golub S. IL-2-induced cytotoxic cells from human thymocytes. Interleukin-2 and Killer Cells in Cancer, R. B. Herberman. CRC Press, Inc., Boca Raton 1990; 97–110, E. Lotzová and assoc. ed.
   Google Scholar
• Muul L. M., Spiess P. J., Director E. P., Rosenberg S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanomas. Cancer Res. 1987; 138: 989–995
   Google Scholar
• Topalian S. L., Muul L. M., Solomon D., Rosenberg S. A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy-trials. J. Immunol. Methods 1987; 102: 127–141
   PubMed Web of Science ®Google Scholar
• Lotzová E., Savary C. A. Growth kinetics, function and characteristics of lymphocytes infiltrating ovarian tumors. Interleukin-2 and Killer Cells in Cancer, R. B. Herberman. CRC Press Inc., Boca Raton 1990; 153–161, E. Lotzová and assoc. ed.
   Google Scholar
• Heo D. S., Whiteside T. L., Johnson J. T., Chen K., Barnes E. L., Herberman R. B. Long-term interleukin-2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes (TIL) from human squamous cell carcinomas of the head and neck. Cancer Res. 1987; 47: 6353–6362
   PubMed Web of Science ®Google Scholar
• Whiteside T. L. Human tumor-infiltrating lymphocytes and their characterization. Interleukin-2 and Killer Cells in Cancer, R. B. Herberman. CRC Press, Inc., Boca Raton 1990; 133–152, E. Lotzová and assoc. ed.
   Google Scholar
• Lotzová E., Savary C. A. Growth kinetics, function and characterization of lymphocytes infiltrating ovarian tumors. Interleukin-2 and Killer Cells in Cancer, R. B. Herberman. CRC Press, Inc., Boca Raton 1991; 153–161, E. Lotzová and assoc. ed.
   Google Scholar
• Itoh K., Balch C. M. Cell-mediated cytotoxicity against fresh solid tumors cells: Regulation by soluble mediators. Interleukin-2 and Killer Cells in Cancer, R. B. Herberman. CRC Press, Inc., Boca Raton 1990; 65–87, E. Lotzová and assoc. ed.
   Google Scholar
• Lotzová E., McCredie K. B., Muesse L., Dicke K. A., Freireich E. J. Natural killer cells in man: Their possible involvement in leukemia and bone marrow transplantation. Experimental Hematology Today, 1979, S. J. Baum, G. D. Ledney. Springer-Verlag, New York 1979; 207–213
   Google Scholar
• Lotzová E., Savary C. A., Keating M. J. Leukemia diseased patients exhibit multiple defects in natural killer cell lytic machinery. Exp. Hematol 1983; 10: 83–95
   Google Scholar
• Lotzová E. Interleukin-2 generated killer cells, their characterization and role in cancer therapy. Cancer Bull. 1987; 39: 30–38
   Google Scholar
• Kiessling R., Klein E., Wigzell H. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 1975; 5: 112–117
   PubMed Web of Science ®Google Scholar
• Kasai M., Yoneda T., Habu S., Maruyama Y., Kkumura K., Tokunaga T. In vivo effect of anti-asialo GM-1 antibody on natural killer activity. Nature 1981; 291: 334–355
   PubMed Web of Science ®Google Scholar
• Warner J., Dennert F. In vivo function of a cloned cell line with NK activity: Effects on bone marrow transplants, tumor development and metastases. Nature 1982; 300: 31–34
   PubMed Web of Science ®Google Scholar
• Abo T., Roder J. C., Abo W., Cooper M. D., Balch C. M. Natural killer (HNK-1 +) cells in Chediak-Higashi patients are present in normal numbers but are abnormal in function and morphology. J. Clin. Invest. 1982; 70: 193–197
   PubMed Web of Science ®Google Scholar
• Lotzová E., Savary C. A., Herberman R. B. Antileukemia reactivity of endogenous and IL-2 activated NK cells. Natural Immunity, Cancer and Biological Response Modification, E. Lotzová, R. B. Herberman. Karger, Basel 1986; 177–195
   Google Scholar
• Lotzová E. The role of natural killer cells in immune surveillance against malignancies. The Cancer Bull. 1984; 36: 215–226
   Google Scholar
• Lotzová E. Cytotoxicity and clinical application of activated NK cells. Medical Oncol, and Tumor Pharmacother. 1989; 6: 93–98
   PubMedGoogle Scholar
• Lotzová E. Natural killer cells: Immunobiology and clinical prospects. Cancer Investigation 1991; 9: 173–184
   PubMed Web of Science ®Google Scholar
• Lotzová E., Savary C. A. Dichotomy in reactivity of IL-2 activated human lymphocyte subsets against normal and malignant hematopoietic cells. Natural Killer Cells: Biology and Clinical Application. Proceedings 6th Int Natural Killer Workshop, Goslar. R. E. Schmidt. Karger, Basel 1990; 280–284
   Google Scholar
• Savary C. A., Lotzová E. Inhibition of human bone marrow and myeloid progenitors by interleukin-2 activated lymphocytes. Exp. Hematol. 1990; 18: 1083–1089
   PubMed Web of Science ®Google Scholar
• Lotzová E., Savary C. A. Bright phenotype of adhesion molecules on lymphocytes with high oncolytic function. NK Cell Mediated Cytotoxicity: Receptors, Signalling and Mechanisms, R. B. Herberman. CRC Press, Inc., Boca Raton, (in press)E. Lotzová and assoc. ed.
   Google Scholar
• Panayotides P., Porwit A., Sjögren A-M., Wasserman J., Reizenstein P. Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells. Eur. J. Haematol. 1988; 40: 362–367
   PubMed Web of Science ®Google Scholar
• Lotzová E., Savary C. A., Cristoforoni P. Triggers involved in NK cells and T lymphocytes oncolysis. NK Cell Mediated Cytotoxicity: Receptors, Signalling and Mechanisms, R. B. Herberman. CRC press, Inc., Boca Raton, E. Lotzová and assoc. ed.(in press)
   Google Scholar
• Fuchshuber P. R., Lotzová E. Feeder cells enhance oncolytic and proliferative activity of long-term human bone marrow IL-2 cultures and induce different lymphocyte subsets. Cancer Immunol. Immunother. 1991; 33: 15–20
   PubMed Web of Science ®Google Scholar
• Lotzová E., Savary C. A., Schachner J. R., Huh J. O., McCredie K. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2. Amer. J. Hematol 1991; 37: 88–99
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T., Seipp C. A., Simpson C., Reichert C. M. Observations on the systemic administration of autologous lymphokine- activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 1985; 23: 1485–1492
   Web of Science ®Google Scholar